Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-15
DOI
10.1007/s10549-018-5008-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Update Breast Cancer 2017 – Implementation of Novel Therapies
- (2017) Michael Lux et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus
- (2017) Michael Untch et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
- (2017) David Cameron et al. LANCET
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients
- (2016) Alexander Hein et al. BREAST CANCER RESEARCH AND TREATMENT
- Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade
- (2016) A. Hennigs et al. BREAST CANCER RESEARCH AND TREATMENT
- Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography
- (2016) Lothar Häberle et al. INTERNATIONAL JOURNAL OF CANCER
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- (2016) Luca Gianni et al. LANCET ONCOLOGY
- Endometriosis as a risk factor for ovarian or endometrial cancer — results of a hospital-based case–control study
- (2015) Stefanie Burghaus et al. BMC CANCER
- Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
- (2015) P. Fasching et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
- (2014) Jessica Salmen et al. BREAST CANCER RESEARCH AND TREATMENT
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
- (2012) Michael Untch et al. LANCET ONCOLOGY
- Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
- (2011) Peter A Fasching et al. BMC CANCER
- Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
- (2011) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
- (2010) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now